Astellas is committed to providing timely and accurate information about our business, science and products. This section offers global resources for investors, journalists and media professionals. News and resources from our local affiliates can be viewed in the Local news section. If you are not an investor or journalist, click here.
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Tokyo, Japan - Nov. 4, 2014 – Astellas Pharma Inc. (Headquarters: Tokyo; President & CEO: Yoshihiko Hatanaka) announced for the fifth consecutive year, Astellas Group’s global volunteer...
BOSTON and TOKYO, JAPAN – Nov. 4th, 2014 – Dana-Farber Cancer Institute (Dana-Farber) and Astellas Pharma Inc. (Tokyo: 4503) today announced a three-year collaboration to research and develop...
Cambridge, Mass. and Tokyo, Japan, November 4th, 2014 -- Proteostasis Therapeutics, Inc. (“Proteostasis Therapeutics”), a company developing novel therapeutics to address diseases caused by...
Chertsey, England – 24th October 2014 – Astellas Pharma Europe Ltd. today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has adopted...
Tokyo, Japan– October 22, 2014 – Astellas Pharma Inc. (TSE: 4503) (“Astellas”) announced the revision of the package insert for the oral androgen receptor signaling inhibitor XTANDI®...
Tokyo, Japan & South San Francisco CA, October 16, 2014 –Astellas Pharma Inc. (TSE: 4503) and CoMentis, Inc. today announced the companies will end their worldwide exclusive collaboration...
Tokyo, October 14th, 2014 --- Astellas Pharma Inc. (Tokyo: 4503, President & CEO: Yoshihiko Hatanaka, “Astellas”) announced today a research collaboration with an investigator at Harvard...
Tokyo, September 16, 2014 - Astellas Pharma Inc. (TSE: 4503; Headquarters: Tokyo; President & CEO: Yoshihiko Hatanaka) announced that it has been selected for the fourth consecutive year for the...
SAN FRANCISCO, CA and TOKYO, JAPAN – September 10, 2014 – Medivation, Inc. (Nasdaq: MDVN) and Astellas Pharma Inc. (Tokyo: 4503) announced today that the U.S. Food and Drug Administration...
Pfizer Japan Inc. (Tokyo, “Pfizer”) and Astellas Pharma Inc. (Tokyo: 4503, “Astellas”) today announced that the companies have agreed to terminate the distribution and co-promotion...
Tokyo, August 29, 2014 - Astellas Pharma Inc. (“Astellas”; TSE: 4503; Headquarters: Tokyo; President & CEO: Yoshihiko Hatanaka), today announced that it has pledged donations of 3 million yen...
Cancer Research UK and its commercial arm, Cancer Research Technology (“CRT”), are to join forces with Astellas Pharma Inc. (Tokyo, President & CEO: Yoshihiko Hatanaka, “Astellas”) to find...
Tokyo, July 14, 2014 - Astellas Pharma Inc. (“Astellas”; Tokyo:4503; President and CEO: Yoshihiko Hatanaka) today announced that it submitted a supplemental new drug application for the...
Astellas today announced it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval for isavuconazole for the treatment of invasive aspergillosis...
Tokyo, Japan, 25 June, 2014 – Astellas Pharma Inc. (“Astellas”; TSE:4503, headquarters: Chuo-ku, Tokyo; president and CEO: Yoshihiko Hatanaka) and UCB Japan Co., Ltd. (“UCB Japan”;...
Astellas Pharma Inc. (TSE: 4503; Headquarters: Tokyo; President & CEO: Yoshihiko Hatanaka) and UMN Pharma Inc. (TSE: 4585；Headquarters: Akita; CEO: Tatsuyoshi Hirano) today announced that...
Chertsey, England [23rd May, 2014] Astellas Pharma Europe Ltd. (APEL), the European Headquarters of Tokyo-based Astellas Pharma Inc., today announces a groundbreaking programme, Action on Fistula,...
Tokyo, Japan– May 23, 2014 – Astellas Pharma Inc. (TSE: 4503) announced that oral androgen receptor signaling inhibitor, XTANDI® Capsules 40mg (generic name: enzalutamide) becomes available...
TOKYO, JAPAN and SAN FRANCISCO, CA – MAY 6, 2014 – Astellas Pharma Inc. (TSE: 4503) and Medivation Inc. (NASDAQ: MDVN) today announced that the U.S. Food and Drug Administration (FDA) has...
TOKYO, April 17, 2014 - Astellas Pharma Inc. (“Astellas”; Tokyo:4503; President and CEO: Yoshihiko Hatanaka) and MSD K.K. (“MSD” ; President and Representative Director: Tony Alvarez)...
Tokyo, Japan, April 1, 2014 - Astellas Pharma Inc. (Tokyo: 4503, President and CEO: Yoshihiko Hatanaka, hereinafter called “Astellas”) has established the "Regenerative Medicine Unit" as of...
Tokyo, Japan– March 24, 2014 – Astellas Pharma Inc. (TSE: 4503) today announced that Astellas has obtained the marketing approval of oral androgen receptor signaling inhibitor, XTANDI®...
Leiden, The Netherlands, March 20, 2014 - The Pediatric Praziquantel Consortium, launched in 2012 as an international non-profit public-private partnership, has announced that it has been awarded...
TOKYO, JAPAN and SAN FRANCISCO, CA – March 18, 2014 – Astellas Pharma Inc. (TSE: 4503) and Medivation Inc. (NASDAQ: MDVN) today announced the submission of a supplemental New Drug Application...
Tokyo, Japan – March 19, 2014 – Astellas Pharma Inc. (“Astellas”; Tokyo: 4503; President and CEO: Yoshihiko Hatanaka) and Daiichi Sankyo Company, Limited (“Daiichi Sankyo,” President...
Tokyo, February 28, 2014 – Astellas Pharma Inc. (Tokyo:4503, “Astellas”) announced today that the company has amended the License, Co-Development and Co-Promotion Agreement on isavuconazole...
CAMBRIDGE, MASS. and TOKYO, JAPAN, February 14, 2014 – AVEO Oncology (NASDAQ: AVEO) and Astellas Pharma Inc. (TSE: 4503) today announced the companies will end their worldwide collaboration and...
SAN FRANCISCO, CA AND TOKYO, JAPAN – January 28, 2014 – Medivation Inc. (NASDAQ: MDVN) and Astellas Pharma Inc. (TSE: 4503) announced final results on the primary and secondary efficacy...
TOKYO, January 17, 2014 - Astellas Pharma Inc. (“Astellas”; Tokyo:4503; President and CEO: Yoshihiko Hatanaka) announced today that it has obtained the marketing approval of selective SGLT2...
Tokyo, January 15, 2014 - Astellas Pharma Inc. (“Astellas Pharma”; Tokyo:4503; President and CEO: Yoshihiko Hatanaka) announced that the orally disintegrating tablet “Irribow® OD 1) Tablets...
Astellas Pharma Inc. (TSE: 4503; Headquaters: Tokyo; President & CEO: Yoshihiko Hatanaka) and UMN Pharma Inc. (TSE: 4585；Headquaters: Akita; CEO: Tatsuyoshi Hirano) today announced that the...
Tokyo, Japan; Rockville, MD; and Epalinges, Switzerland – January 6, 2014 – Astellas Pharma Inc. (Astellas) and ClearPath Development Company (ClearPath) announced today a strategic...
Tokyo, December 25, 2013 - Astellas Pharma Inc. (“Astellas”) and Immuno-Biological Laboratories Co., Ltd. (“IBL”) today announced that they have concluded a collaborative research...
Tokyo, December 20, 2013 - Astellas Pharma Inc. (“Astellas”; Tokyo: 4503; President and CEO: Yoshihiko Hatanaka) announced the approval of an additional indication for hypnosedative,...
Tokyo, December 13, 2013 – Astellas Pharma Inc. (Headquarters: Tokyo, President and CEO: Yoshihiko Hatanaka, hereinafter called “the Company”) announced that it completed acquisition of its...
Tokyo, December 13, 2013 - Astellas Pharma Inc. (“Astellas”; headquarters : Tokyo:4503; President and CEO: Yoshihiko Hatanaka), today announced that a definitive agreement has been concluded...
Tokyo and Boston, October 7, 2013 --- Astellas Pharma Inc. (Tokyo Stock Exchange: 4503, President and CEO: Yoshihiko Hatanaka, hereinafter called “Astellas”) and Mitokyne, Inc. (President and...
TOKYO, December 5, 2013 – On December 4, 2013, Astellas Pharma Inc. (“Astellas”; Tokyo:4503; President and CEO: Yoshihiko Hatanaka), reached and entered into an agreement with Mitsui Fudosan...
Tokyo, November 15, 2013–Astellas Pharma Inc. (“Astellas,” Tokyo: 4503) and the Astellas Asia-Oceania Foundation* has pledged donations totaling US $70,000 to support victims of typhoon...
Tokyo, November 1, 2013 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, “Astellas”) has signed an agreement with Accenture Japan Ltd. (headquarters: Tokyo, President:...
San Francisco, CA and Tokyo – October 22, 2013 – Medivation, Inc. (Nasdaq: MDVN) and Astellas Pharma Inc. (TSE: 4503) today announced that the Independent Data Monitoring Committee (IDMC) has...
Astellas Pharma Inc. (TSE: 4503; Headquaters: Tokyo; President & CEO: Yoshihiko Hatanaka) and UMN Pharma Inc. (TSE: 4585; Headquaters: Akita; CEO: Tatsuyoshi Hirano) today announced that the...
Tokyo, Japan, October 1, 2013 - Astellas Pharma Inc. (Tokyo: 4503, President and CEO: Yoshihiko Hatanaka, hereinafter called “Astellas”) established today Innovation Management (“AIM”), as...
Astellas Pharma Inc. (“Astellas”; headquarters : Tokyo:4503; President and CEO : Yoshihiko Hatanaka) today announced that a basic agreement has been concluded between Astellas Pharma Tech Co.,...
Tokyo: September 9, 2013 - Toa Eiyo Ltd. (Tokyo; Unlisted; “Toa Eiyo”) and Astellas Pharma Inc. (Tokyo: 4503; “Astellas”) announced today that, on September 10, 2013, Toa Eiyo and Astellas...
TOKYO, September 2, 2013 -- Astellas Pharma Inc. (“Astellas”; Tokyo:4503; President and CEO: Yoshihiko Hatanaka) and MSD K.K. (“MSD” ; President and Representative Director: Tony Alvarez)...
An international public-private partnership (PPP) was launched in July last year to develop a new pediatric formulation to combat schistosomiasis – commonly known as bilharzia – in preschool...
NORTHBROOK, Ill. August 22, 2013 – Astellas Pharma US, Inc. (“Astellas”), a U.S. subsidiary of Tokyo-based Astellas Pharma Inc. (Tokyo: 4503), announced today that ASTAGRAF XLTM (tacrolimus...
Tokyo, August 15, 2013 - Astellas Pharma Inc. (“Astellas Pharma”; Tokyo:4503; President and CEO: Yoshihiko Hatanaka) announced that it has obtained the marketing approval of Irribow® OD 1)...
Tokyo and San Francisco -- July 30, 2013 -- Astellas Pharma Inc. (Tokyo:4503) (Astellas) and FibroGen, Inc. (FibroGen) announced today the initiation of a Phase 2 clinical study in Japan of...
NORTHBROOK, Ill. July 19, 2013 – Astellas Pharma US, Inc. (“Astellas”), a U.S. subsidiary of Tokyo-based Astellas Pharma Inc. (Tokyo: 4503), announced today that the U.S. Food and Drug...
Astellas Pharma Inc. (Headquarters: Tokyo; President and CEO: Yoshihiko Hatanaka, hereinafter called the “Company”) today announced that it decided the contents of the stock acquisition rights...
Tokyo: June 28, 2013 – Toa Eiyo Ltd. (Tokyo; Unlisted; “Toa Eiyo”) and Astellas Pharma Inc. (Tokyo: 4503; “Astellas”) announced today that Toa Eiyo has obtained the marketing approval...
BOTHELL, Wash., & SANTA MONICA, Calif., June 27, 2013 – Seattle Genetics, Inc. (Nasdaq: SGEN) and Agensys, Inc., an affiliate of Tokyo-based Astellas Pharma Inc. (Tokyo:4503), today announced...
San Francisco, CA and Tokyo – June 26, 2013 – Medivation, Inc. (Nasdaq: MDVN) and Astellas Pharma Inc. (TSE: 4503) today announced enrollment of the first patient in a global Phase 2 clinical...
SAN DIEGO & TOKYO—June 25, 2013—Vical Incorporated (Nasdaq: VICL) and Astellas Pharma Inc. (TOKYO: 4503) today announced the initiation of a multinational Phase 3 registration trial of ASP0113...
South San Francisco, CA, and Tokyo, June 25, 2013 – Cytokinetics, Incorporated (NASDAQ:CYTK) and Astellas Pharma Inc. (Tokyo Stock Exchange: 4503, "Astellas") announced today a collaboration...
Tokyo, June 18, 2013 - Astellas Pharma Inc. (Tokyo: 4503; “Astellas”) and Kyoto University’s Center for iPS Cell Research and Application (Director: Dr. Shinya Yamanaka; “CiRA”), as a...
TOKYO, June 14, 2013 - Astellas Pharma Inc. (“Astellas”; Tokyo:4503; President and CEO: Yoshihiko Hatanaka) announced today that it has been granted approval in Japan for the additional...
TOKYO, Japan, June 11, 2013 -Astellas Pharma Inc. (TSE: 4503) today announced that AVEO has received a Complete Response Letter from the U.S. Food and Drug Administration (FDA) informing the...
Tokyo, June 5, 2013 - Zeria Pharmaceutical Co., Ltd. (Tokyo: 4559; “Zeria”) and Astellas Pharma Inc. (Tokyo: 4503; “Astellas”) announced today that Acofide® Tablets 100mg (nonproprietary...
Tokyo and San Francisco, CA – June 3, 2013 – Astellas Pharma Inc. (TSE: 4503) and Medivation, Inc. (Nasdaq: MDVN) today announced that after a priority review, Health Canada has approved XTANDI®
Tokyo Japan, May 31, 2013 - Nippon Boehringer Ingelheim Co., Ltd. (headquartered in Shinagawa-ku, Tokyo; president, Yoshiaki Aono; hereinafter referred to as “Nippon Boehringer Ingelheim”) and...
THOUSAND OAKS, Calif., and TOKYO (May 29, 2013) – Amgen (NASDAQ:AMGN), the world’s largest independent biotechnology company, and Astellas Pharma Inc. (Tokyo Stock Exchange: 4503,...
Tokyo, May 28, 2012 – Astellas Pharma Inc. (Tokyo:4503) announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to isavuconazole for the treatment of...
Tokyo, Japan and San Francisco, CA – May 24, 2013 – Astellas Pharma Inc. (TSE: 4503) and Medivation, Inc. (NASDAQ: MDVN) today announced that Astellas has submitted an application for...
SOUTH SAN FRANCISCO, Calif. and NORTHBROOK, Ill. – May 14, 2013 – Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) and Astellas Pharma US, Inc. (“Astellas”), a U.S....
CAMBRIDGE, Mass. and TOKYO, Japan, May 15, 2013 - AVEO Oncology (NASDAQ: AVEO) and Astellas Pharma Inc. (TSE: 4503) today announced that additional data from the Phase 3 TIVO-1 trial (TIvozanib...
Tokyo, Japan, May 14, 2013 - Astellas Pharma Inc. (Tokyo：4503, President and CEO: Yoshihiko Hatanaka, hereinafter called “Astellas”) today announced plans to reshape its research framework...
Follow us
